ArticleSignal transduction and targeted therapy2021
The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2.
Article in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 38 citations in OpenAlex.
- Production and Immunogenicity Assessment of LTp50: AnPharmaceuticals (Basel, Switzerland) · 2024Article
- The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex.Future virology · 2023Article
- A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site.Vaccines · 2023Article
- Implementation of an In-House Platform for Rapid Screening of SARS-CoV-2 Genome Variations.Archives of Iranian medicine · 2023Article
- Development of primer-probe sets to rapidly distinguish single nucleotide polymorphisms in SARS-CoV-2 lineages.Frontiers in cellular and infection microbiology · 2023Article
- Omicron variant: Current insights and future directions.Microbiological research · 2022Review
- Persistent Laplacian projected Omicron BA.4 and BA.5 to become new dominating variants.Computers in biology and medicine · 2022Article
- Structural Profiles of SARS-CoV-2 Variants in India.Current microbiology · 2022Article
- Disease Waves of SARS-CoV-2 in Iran Closely Mirror Global Pandemic Trends.Archives of Iranian medicine · 2022Article
- Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants.Microbiology spectrum · 2022Article
- Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant.The journal of physical chemistry letters · 2022Article
- Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.Cell · 2022Article
- SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia.Acta bio-medica : Atenei Parmensis · 2022Article
- Emerging Vaccine-Breakthrough SARS-CoV-2 Variants.ACS infectious diseases · 2022Article
- Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant.Research square · 2022Article
- Article
- Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.Journal of chemical information and modeling · 2022Article
- Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis.Scientific reports · 2022Article
- Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19.Viruses · 2022Review
- Nanoagent-based theranostic strategies against human coronaviruses.Nano research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.